Intravenous Infusion of Prostaglandins as Therapy in Patients With Anterior Non-arteritic Ischemic Optic Neuropathy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

24 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-06-13

Study Completion Date

2019-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Correction of the deficit in the perfusion pressure of the microcirculation that supplies the nerve by intravenous infusion of Prostaglandin E1 (PGE1) (Alprostadil), expected to improve visual function in patients with ischemic optic neuropathy previous non-arteritic (NOIANA).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study to Assess the Efficacy and Safety of Monthly Octreotide Intramuscular Injections in Patients With Proliferative Diabetic Retinopathy After Lasercoagulation This Study is Not Being Conducted in the United States.

NCT00170742

Proliferative Diabetic Retinopathy

TERMINATED PHASE3

Intranasal Delivery of Octreotide for Treatment of Diabetic Macular Edema

NCT06881888

Diabetic Macular Edema

NOT_YET_RECRUITING PHASE1

Effect of Intravenous Methylprednisolone and Intravenous Erythropoietin in Toxic Optic Neuropathies: Randomized Clinical Trial.

NCT05748561

Toxic Optic Neuropathy Treatment Methylprednisolone +1 more

UNKNOWN PHASE2/PHASE3

Platelet-Rich Plasma for Acute Nonarteritic Anterior Ischemic Optic Neuropathy: A Prospective Randomized Controlled Study

NCT07330713

Nonarteritic Anterior Ischemic Optic Neuropathy

COMPLETED NA

Microneedle Intra-Arterial Injection for Retinal Artery Occlusion

NCT07151755

Central Retinal Artery Occlusion

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ischemic Optic Neuropathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Alprostadil 20 micrograms

1 μg / kg patient weight up to a maximum of 60 μg

Group Type EXPERIMENTAL

Alprostadil 20 micrograms

Intervention Type DRUG

Intravenous infusion of PGE1 (Days 0, +1 and +2)

Placebo (physiological saline solution)

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Intravenous infusion of physiological saline solution

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Alprostadil 20 micrograms

Intravenous infusion of PGE1 (Days 0, +1 and +2)

Intervention Type DRUG

Placebo

Intravenous infusion of physiological saline solution

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients of both sexes between the ages of 50 and 80, both inclusive. Patients with the first episode of ischemic optic neuropathy previous non-arteritic / NOIANA. Patients with NOIANA with an evolution time from the beginning of the clinic less than or equal to 15 days.
* Potentially fertile patients should have a negative pregnancy test in serum (beta-HCG / human chorionic gonadotropin) or urine.
* Patients who offer sufficient guarantees of adherence to the protocol.
* Patients who give written informed consent to participate in the study.

Exclusion Criteria

* Patients with previous optic of any etiology in the affected eye.
* Patients with previous diagnosis or symptoms at the time of arteritis of the temporal artery.
* Patients with optic neuropathy with bilateral clinical presentation of any etiology.
* Patients with loss of vision due to acute hypotension in the context of a surgical intervention, acute hemorrhage or hemodynamic shock.
* Patients with severe loss of previous vision in the eye affected by ophthalmologic causes: severe cataract, glaucoma or intraocular pressure greater than 30 millimeters of mercury, severe diabetic retinopathy, macular degeneration associated with severe age.
* Patients with clinical onset in the month following major non-ocular or intraocular surgery
* Patients with abnormal elevation of CRP / C-reactive protein (\> 2 times the upper limit of normal)
* Patients with creatinine levels above 1.5 mg / dL.
* Patients on steroid treatment in the month prior to the episode.
* Patients under treatment with oral anticoagulants.
* Patients on treatment with hydroxychloroquine, ethambutol, vigabatrin at any time before the episode.
* Patients in whom the use of PGE1 (Alprostadil) is contraindicated:
* Patients with participation in a clinical trial in the last 6 months.
* Patients with inability to understand informed consent.
* Pregnant patients, in the postpartum period or during the active lactation period.
* Physically fertile patients

Minimum Eligible Age

50 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No